CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
Published on January 16, 2018
Corbus Pharmaceuticals Holdings, Inc.
100 River Ridge Drive
Norwood, MA 02062
January 16, 2018
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Corbus Pharmaceuticals Holdings, Inc. | |
| Registration Statement on Form S-3 (File No. 333-222447) | ||
| Filed on January 5, 2018 |
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, Corbus Pharmaceuticals Holdings, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission (the “Commission”) at 4:30 p.m., Eastern Standard Time, on January 17, 2018, or as soon as practicable thereafter.
Please call Steven M. Skolnick of Lowenstein Sandler LLP at (973) 597-2476 to confirm the effectiveness of the Registration Statement or with any questions.
[Signature page follows.]
U.S. Securities and Exchange Commission
January 16, 2018
Page 2
| Very truly yours, | ||
| CORBUS PHARMACEUTICALS | ||
| HOLDINGS, INC. | ||
| By: | /s/ Sean Moran | |
| Name: | Sean Moran | |
| Title: | Chief Financial Officer | |
| -2- |